MX2013015001A - Formas solidas y sales de derivados de tetrahidro-pirido-pirimidin a. - Google Patents
Formas solidas y sales de derivados de tetrahidro-pirido-pirimidin a.Info
- Publication number
- MX2013015001A MX2013015001A MX2013015001A MX2013015001A MX2013015001A MX 2013015001 A MX2013015001 A MX 2013015001A MX 2013015001 A MX2013015001 A MX 2013015001A MX 2013015001 A MX2013015001 A MX 2013015001A MX 2013015001 A MX2013015001 A MX 2013015001A
- Authority
- MX
- Mexico
- Prior art keywords
- forms
- pyrido
- tetrahydro
- salts
- solid forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención se refiere a las formas anhidras cristalinas, a las formas de solvato cristalinas y/o a las formas de sales, incluyendo las formas de sales cristalinas de la {(S)-3-[6-(6-metoxi-5-metil- piridin-3-il)-5,6,7,8-tetrahidro-piri do-[4,3-d]-pirimidin-4-iloxi]-pirrolidin-1-il}-(tetrahidro-piran- 4-il)-metanona, o a las formas de sales, incluyendo las formas de sales cristalinas de la 1-{(S)-3-[6-(6- metoxi-5-trifluoro-metil-p iridin-3-il)-5,6,7,8-tetrahidro-pirido-[4,3-d]-pirimidin-4-il-ami no]-pirrolidin-1-il}-propan-1-ona; a composiciones farmacéuticas y combinaciones que incluyen estas formas, así como a los métodos para utilizar estas formas, incluyendo sus composiciones farmacéuticas y combinaciones para el tratamiento de enfermedades.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IR1390040156 | 2011-06-27 | ||
PCT/IB2012/053209 WO2013001445A1 (en) | 2011-06-27 | 2012-06-25 | Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2013015001A true MX2013015001A (es) | 2014-03-31 |
Family
ID=50231547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013015001A MX2013015001A (es) | 2011-06-27 | 2012-06-25 | Formas solidas y sales de derivados de tetrahidro-pirido-pirimidin a. |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP2723740A1 (es) |
JP (1) | JP2014518256A (es) |
KR (1) | KR20140025530A (es) |
CN (1) | CN103608349A (es) |
AU (1) | AU2012277391A1 (es) |
CA (1) | CA2840315A1 (es) |
CL (1) | CL2013003567A1 (es) |
CO (1) | CO6821957A2 (es) |
EA (1) | EA201490164A1 (es) |
MA (1) | MA35203B1 (es) |
MX (1) | MX2013015001A (es) |
SG (1) | SG195067A1 (es) |
TN (1) | TN2013000483A1 (es) |
WO (1) | WO2013001445A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3251673A1 (en) | 2012-12-13 | 2017-12-06 | IP Gesellschaft für Management mbH | Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer |
CN104945367A (zh) * | 2015-06-04 | 2015-09-30 | 聂超 | 一种苯甲醛丙二醇缩醛及其制备方法 |
AU2017204936B2 (en) * | 2016-02-10 | 2019-06-27 | Novartis Ag | Use of inhibitors of the activity or function of PI3K for the treatment of primary Sjogren's Syndrome |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
ATE28864T1 (de) | 1982-07-23 | 1987-08-15 | Ici Plc | Amide-derivate. |
GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
TW225528B (es) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
BR9609617B1 (pt) | 1995-07-06 | 2010-07-27 | derivados de 7h-pirrol[2,3-d]pirimidina, e composição farmacêutica. | |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
CA2249446C (en) | 1996-04-12 | 2008-06-17 | Warner-Lambert Company | Irreversible inhibitors of tyrosine kinases |
WO1997049688A1 (en) | 1996-06-24 | 1997-12-31 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
JP2001500851A (ja) | 1996-08-30 | 2001-01-23 | ノバルティス アクチエンゲゼルシャフト | エポシロンの製造法および製造過程中に得られる中間生産物 |
EP0938597B1 (en) | 1996-09-06 | 2003-08-20 | Obducat Aktiebolag | Method for anisotropic etching of structures in conducting materials |
CA2265630A1 (en) | 1996-09-13 | 1998-03-19 | Gerald Mcmahon | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
CN100344627C (zh) | 1996-11-18 | 2007-10-24 | 生物技术研究有限公司(Gbf) | 埃坡霉素c、其制备方法以及作为细胞抑制剂和植物保护剂的应用 |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
IL138113A0 (en) | 1998-02-25 | 2001-10-31 | Sloan Kettering Inst Cancer | Synthesis of epothilones, intermediates thereto and analogues thereof |
ES2342240T3 (es) | 1998-08-11 | 2010-07-02 | Novartis Ag | Derivados de isoquinolina con actividad que inhibe la angiogenia. |
KR100716272B1 (ko) | 1998-11-20 | 2007-05-09 | 코산 바이오사이언시즈, 인코포레이티드 | 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질 |
PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
NZ525656A (en) | 2000-11-07 | 2004-12-24 | Novartis Ag | Indolylmaleimide derivatives as protein kinase C inhibitors |
AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
TW200918046A (en) | 2002-04-03 | 2009-05-01 | Novartis Ag | Indolylmaleimide derivatives |
US7365096B2 (en) | 2002-12-09 | 2008-04-29 | Board Of Regents, The University Of Texas System | Methods for selectively inhibiting Janus tyrosine kinase 3 (Jak3) |
ZA200602666B (en) | 2004-01-12 | 2007-09-26 | Cytopia Res Pty Ltd | Selective kinase inhibitors |
ES2427999T3 (es) * | 2007-04-17 | 2013-11-05 | Evotec Ag | Compuestos heterocíclicos 2-cianofenil-condensados y composiciones y usos de los mismos |
UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
-
2012
- 2012-06-25 CN CN201280030091.2A patent/CN103608349A/zh not_active Withdrawn
- 2012-06-25 EA EA201490164A patent/EA201490164A1/ru unknown
- 2012-06-25 WO PCT/IB2012/053209 patent/WO2013001445A1/en active Application Filing
- 2012-06-25 SG SG2013085923A patent/SG195067A1/en unknown
- 2012-06-25 EP EP12738616.7A patent/EP2723740A1/en not_active Withdrawn
- 2012-06-25 KR KR1020137034120A patent/KR20140025530A/ko not_active Application Discontinuation
- 2012-06-25 MX MX2013015001A patent/MX2013015001A/es not_active Application Discontinuation
- 2012-06-25 JP JP2014518016A patent/JP2014518256A/ja not_active Withdrawn
- 2012-06-25 CA CA2840315A patent/CA2840315A1/en not_active Withdrawn
- 2012-06-25 AU AU2012277391A patent/AU2012277391A1/en not_active Abandoned
-
2013
- 2013-11-19 TN TNP2013000483A patent/TN2013000483A1/fr unknown
- 2013-12-12 CO CO13291228A patent/CO6821957A2/es not_active Application Discontinuation
- 2013-12-12 CL CL2013003567A patent/CL2013003567A1/es unknown
- 2013-12-20 MA MA36600A patent/MA35203B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
CN103608349A (zh) | 2014-02-26 |
MA35203B1 (fr) | 2014-06-02 |
AU2012277391A1 (en) | 2013-12-19 |
KR20140025530A (ko) | 2014-03-04 |
EA201490164A1 (ru) | 2014-04-30 |
JP2014518256A (ja) | 2014-07-28 |
EP2723740A1 (en) | 2014-04-30 |
WO2013001445A1 (en) | 2013-01-03 |
CL2013003567A1 (es) | 2014-08-08 |
TN2013000483A1 (en) | 2015-03-30 |
CA2840315A1 (en) | 2013-01-03 |
CO6821957A2 (es) | 2013-12-31 |
SG195067A1 (en) | 2013-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016502168A1 (en) | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
TN2010000305A1 (en) | Pyrrolopyrimidines and pyrrolopyridines | |
GEP201706774B (en) | Heterocyclyl compounds | |
GEP20156417B (en) | Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases | |
PH12018500532A1 (en) | 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer | |
IL235659A0 (en) | History of 3, 4 - dihydro -2h - pyrido [1, 2 - a] pyrazine - 1,2,1] 6 converted diones used to treat (among others) Alzheimer's disease | |
MX363715B (es) | Formas solidas de un inhbidor de cdk4/6 selectivo. | |
ZA201000079B (en) | Organic compounds | |
TN2010000167A1 (en) | Organic compounds | |
MY164274A (en) | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof | |
MY150747A (en) | Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer | |
IN2014DN06781A (es) | ||
MX336332B (es) | Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia. | |
WO2014053968A8 (en) | Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors | |
TN2013000483A1 (en) | Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives | |
TN2013000377A1 (en) | Thieno [2, 3-d] pyrimidine derivatives and their use to treat arrhythmia | |
TN2015000128A1 (en) | Solid form of dihydro-pyrido-oxazine derivative | |
PH12018501490A1 (en) | Use of inhibitors of the activity or function of pi3k for the treatment of primary sjgren's syndrome | |
TN2013000146A1 (en) | Salt(s) of 7-cyclopentyl-2 -(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof | |
NZ622594A (en) | Pyrazoloquinoline derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |